KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) EPS (Weighted Average and Diluted) (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with $26.39 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 203.21% to $26.39 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.65 through Dec 2025, up 142.51% year-over-year, with the annual reading at $27.85 for FY2025, 142.61% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $26.39 at Bio-Rad Laboratories, up from -$12.7 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $130.02 in Q3 2021, with the low at -$112.5 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.99, with a median of $2.98 recorded in 2023.
  • The sharpest move saw EPS (Weighted Average and Diluted) tumbled 446.58% in 2022, then surged 541.21% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$52.54 in 2021, then soared by 152.87% to $27.78 in 2022, then plummeted by 56.3% to $12.14 in 2023, then plummeted by 310.63% to -$25.57 in 2024, then soared by 203.21% to $26.39 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $26.39, -$12.7, and $11.67 for Q4 2025, Q3 2025, and Q2 2025 respectively.